Table 3.
Antibiotic susceptibility rates according to the occurrence of severe complications attributable to viridans streptococcal bacteremia
| Antibiotics | All patients*(n=201) | Without complications (n=175) | With complications (n=26) | p-value |
|---|---|---|---|---|
| Penicillin |
79/201 (39.3) |
70/175 (40.0) |
9/26 (34.6) |
0.600 |
| Cefotaxime† |
166/200 (83.0) |
142/174 (81.6) |
24/26 (92.3) |
0.263 |
| Cefepime‡ |
159/199 (79.9) |
136/173 (78.6) |
23/26 (88.5) |
0.243 |
| Vancomycin |
201/201 (100.0) |
175/175 (100.0) |
26/26 (100.0) |
NA |
| Linezolid |
200/201 (99.5) |
174/175 (99.4) |
26/26 (100.0) |
1.000 |
| Clindamycin |
172/201 (85.6) |
151/175 (86.3) |
21/26 (80.8) |
0.548 |
| Erythromycin | 99/201 (49.3) | 86/175 (49.1) | 13/26 (50.0) | 0.935 |
Data are No. (%) of cases.
NA not available.
*Antibiotic susceptibility tests were performed in 201 patients (175 without severe complications, 26 with severe complications).
†Antibiotic susceptibility tests were performed in 200 patients (174 without severe complications, 26 with severe complications).
‡Antibiotic susceptibility tests were performed in 199 patients (173 without severe complications, 26 with severe complications).